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Abstract: A point mutation in the DNA polymerase gene in equine herpesvirus type 1 (EHV-1) is
one determinant for the development of neurological disease in horses. Three recently conducted
infection experiments using domestic horses and ponies failed to detect statistically significant
differences in viral shedding between the neuropathogenic and non-neuropathogenic variants.
These results were interpreted as suggesting the absence of a consistent selective advantage of
the neuropathogenic variant and therefore appeared to be inconsistent with a systematic increase in
the prevalence of neuropathogenic strains. To overcome potential problems of low statistical power
related to small group sizes in these infection experiments, we integrated raw data from all three
experiments into a single statistical analysis. The results of this combined analysis showed that
infection with the neuropathogenic EHV-1 variant led to a statistically significant increase in viral
shedding. This finding is consistent with the idea that neuropathogenic strains could have a selective
advantage and are therefore systematically increasing in prevalence in domestic horse populations.
However, further studies are required to determine whether a selective advantage indeed exists for
neuropathogenic strains.
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1. Introduction
Equine herpesvirus type 1 (EHV-1) is a ubiquitous alphaherpesvirus that can cause respiratory
disease, abortion, neonatal foal death and equine herpes myeloencephalopathy (EHM), a neurological
disease that can be lethal [1,2]. Although it is not well understood how EHM develops following EHV-1
infection, it has been shown that neuropathogenicity is significantly associated with a single nucleotide
polymorphism in the viral DNA polymerase, resulting in a specific amino acid change; asparagine
to aspartic acid (N/D752) [1–3]. To demonstrate the causality of this association, mutations were
introduced in the backgrounds of representative D752 and N752 strains from Europe and North America,
cloned as bacterial artificial chromosomes and then characterized thoroughly both in vitro and
in vivo [4,5]. Although involvement of a variety of host, viral, and environmental risk factors are
known or suspected, infections with D752 strains strongly increase the risk of developing EHM [1].
Based on two retrospective large-scale studies, it has been estimated that the odds of having EHM
with a D752 strain were 490 times greater than those with a N752 strain [2].
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Whether the neuropathogenic D752 strains are increasing in prevalence and what could enable
such an increase are important and as yet unresolved questions. The D752 or the N752 at synonymous
positions in DNA polymerases of other herpesviruses is highly conserved [3], although EHM has
been considered rare in the past. Following worldwide EHM outbreaks in 2006–2007, the US
Department of Agriculture classified EHM as a potentially emerging disease [6]. Related concerns
that neuropathogenic D752 strains are spreading in domestic horse populations have been supported
by a limited number of large-scale retrospective studies. These studies indicated that while N752
strains are more common [2,7], D752 strains have increased in prevalence in recent decades [8], which
may suggest the existence of a selective advantage of neuropathogenic D752 strains. However, what
could mediate such a selective advantage remains unclear. In contrast to the potential fitness benefits,
D752 strains might suffer from fitness costs related to increased host death rates that result from
neuropathogenicity [9].
D752 strains might have nevertheless a selective advantage if they have sufficiently increased
transmission rates compared to N752 strains. EHV-1 transmission occurs via direct contact, fomites,
or by inhalation of respiratory secretions [2]. Primary infections caused by EHV-1 occur at the
respiratory epithelium and result in nasal shedding for 10 to 14 days. These infections typically result
in life-long latent infections with subsequent viral reactivation and viral shedding during periods of
stress [1]. Differences in transmission rates among strains can therefore have at least three causes:
(1) the differences in the amount of nasal virus shedding during primary infections; (2) differences
in the amount of nasal virus shedding at reactivation; and (3) differences in the rate of reactivation.
Among these sources, previous studies have been limited to investigations of viral shedding during
primary infections. Specifically, two experimental infection studies, which document that the D752
variant is more likely to cause neuropathogenicity, failed to find evidence that infections with the
D752 variant cause statistically significant increased amounts of nasal virus shedding compared to the
N752 variant [4,5]. These results were interpreted as suggesting the absence of a consistent selective
advantage of the D752 variant and therefore were thought to indicate the absence of a systematic
increase in the prevalence of neuropathogenic D752 strains.
Here, we re-examined data from the two previous studies to address the potential problem that
the absence of statistically significant differences in shedding amounts reflected an actual absence
of differences; and the absence of statistical significance could be related to low statistical power.
To overcome potential problems of low statistical power related to small sample sizes, we integrated
the original raw data from all three experimental infection studies into a single statistical analysis
and re-assessed whether increased neuropathogenicity of the D752 variant coincides with increased
viral shedding.
2. Materials and Methods
In our analysis, we integrated data on nasal virus shedding from infection experiments conducted
by Goodman et al. [4] and Van de Walle et al. [5]. Both studies used a similar experimental design in
which two groups of animals were infected with the N752 or D752 EHV-1 variant (Table 1). However,
the performed experiments differed in specific details that include infection dose, breed of studied
animals and number of infected animals. Goodman et al. conducted two separate experiments: (1) two
groups of four Welsh Mountain ponies infected with 7 × 106 plaque-forming units (PFUs) of the virus,
and (2) two groups of seven mixed-breed horses infected with 1 × 107 PFUs [4]. Van de Walle et al.
conducted one experiment on a group of three and six horses (infected with the N752 and D752
variant, respectively), which were each inoculated with 1.5 × 107 PFUs [5]. Following infection,
nasal swabs were obtained from each animal at a daily or near-daily basis (Figure 1). For all three
experiments, quantitative polymerase chain reaction was used to measure the amount of nasal virus
shedding and estimate the viral genome copy number in nasal swabs. All three experiments were
performed in accordance with relevant guidelines and regulations. The experimental protocols on
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horses were approved by the Cornell University Institutional Animal Care and Use Committee [4,5].
The experimental protocol on ponies was approved by the UK Home Office [4].






Animals Infected Estimated Viral Genome Copy Numbers
1
N752 D752 N752 D752
Horses 2007 [4] 178 13 7 7 5.2 × 106 ± 3.1 × 107 1.2 × 107 ± 3.6 × 107
Horses 2009 [5] 108 12 6 3 3.5 × 105 ± 1.2 × 106 5.2 × 107 ± 4.4 × 108
Ponies 2007 [4] 96 12 4 4 9.5 × 105 ± 3.7 × 106 1.4 × 106 ± 4.0 × 106
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Figure 1. Boxplots illustrating the differences in amounts of nasal virus shedding between equine
herpesvirus type 1 (EHV-1) variants (N/D752) across all days and animals for each experiment.
(a) Experiment on 14 horses (seven infected with the N752 and seven infected with the D752 variant)
conducted by Goodman et al. [4]; (b) Experiment on nine horses (three infected with the N752 and six
infected with the D752 variant) conducted by Van de Walle et al. [5]; (c) Experiment on eight ponies
(four infected with the N752 and four infected with the D752 variant) conducted by Goodman et al. [4].
If sampling took place on a given day, then all infected animals were sampled, with the exception
of day 23 in the experiment on horses conducted by Goodman et al. where samples were restricted
to six individuals infected with the N752 variant and four individuals infected with the D752 variant.
In each boxplot, the bottom and top of the box indicate the first and third quartiles, and the band inside
the box indicates the median. Upper (and lower) whiskers extend to the highest (and lowest) value
that is within 1.5 times the inter-quartile range (i.e., the distance between the first and third quartiles).
Data points beyond the end of the whiskers are plotted as dots [10]. Due to highly skewed distributions,
the amount of nasal virus shedding was plotted on a logarithmic scale.
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In our statistical analysis, we aimed to test whether amounts of nasal virus shedding differed
between the two EHV-1 variants. We focused only on shedding amount and did not analyze shedding
duration because the majority of animals (17 out of 31) were still shedding on the last respective
sampling day. To maximize statistical power in our analysis of nasal virus shedding, we pooled
all available raw data from the three experiments. Accordingly, our data set consisted of 382 data
points, where each data point was related to one individual measure of nasal virus shedding (Table 1,
Figure 1). This approach required the analysis to appropriately control for non-independence of
data points and related variation in shedding amounts that emerged from (1) consistent differences
among animals, which might, for example, relate to physiological or genetic differences; (2) systematic
differences among the three experiments, which could, for example, relate to differences in infection
treatment or horse breeds; and (3) temporal variation in shedding over the course of each experiment.
To address these issues, we used a linear mixed model, in which each nasal swab was treated as
a single data point with the amount of nasal virus shedding as the response variable. The EHV-1
variant (N752 vs. D752) was treated as a fixed effect, which tested whether shedding differed between
the two EHV-1 variants. To account for variation in nasal virus shedding among experiments
and over time within each experiment, we included a categorical predictor ‘experiment_day’ as
a fixed effect in our model. This predictor combines information on the experiment and day after
infection, which resulted in 37 unique levels (13 + 12 + 12 days). To account for potential differences
among animals and non-independence of data points, the identity of each animal was included as a
random effect. To prevent violations of model assumptions, we log-transformed the response variable.
After this transformation, visual inspections of the model output did not indicate any violations of
assumptions regarding the normality and homogeneity of error variances. Model fitting and analysis
were performed using the package ‘glmmADMB’ [11] in the statistical software R [12]. Statistical
significance was assessed based on a two-sided test with an α-level of 0.05. The datasets supporting
this article are available from the Dryad Digital Repository [13].
3. Results
Results of our combined analysis showed that the amount of EHV-1 nasal shedding was
significantly increased in animals infected with the D752 variant compared with infection with the
N752 variant (p = 0.001). The model indicated that infections with the D752 variant led, on average,
to a four-fold higher amount of nasal EHV-1 shedding compared to infections with the N752 variant
(Figure 1). To control for potentially confounding effects of combining data on mixed-breed horses
and Welsh Mountain ponies, we also performed an analysis that excluded the pony data (Figure 1c).
The analysis of this reduced data set did not qualitatively change our results: the differences between
both variants remained significant (p = 0.004) with an estimated 3.9-fold increase in the amount of
nasal virus shedding by animals infected with the neuropathogenic D752 variant.
4. Discussion
In contrast to previously conducted and separately analyzed studies, we found support for
the hypothesis that, compared to the non-neuropathogenic N752 variant, primary infection with
neuropathogenic D752 results in increased nasal virus shedding. This finding indicates that the absence
of statistical differences in shedding amounts in previous studies was related to low statistical power.
Given the constraints of performing infection experiments on a large number of animals, our findings
emphasize (1) the importance of using advanced statistical modeling approaches and (2) the usefulness
of pooling raw data from individual experiments.
Our finding of increased nasal virus shedding of the D752 variant following experimental
EHV-1 infections of equids is consistent with the idea that D752 strains could have a selective
advantage and are therefore systematically increasing in prevalence in domestic horse populations [8].
However, our finding is not sufficient to determine whether a fitness advantage indeed exists
for D752 variants, which would require more precise information on infection-induced host death
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rates and rates of viral reactivation during latent infections. In addition, due to effects on host
death and transmission rates, the fitness of different EHV-1 strains might be strongly determined
by within-host interactions. Co-infection with both variants is possible [1,7], which suggests that
within-host interactions between different strains might occur, which could impact strain fitness
and related evolutionary dynamics [14,15]. We are not aware of any study that has investigated
within-host interactions between the two variants. Nevertheless, there is some indication that the
neuropathogenic variant has a competitive advantage regarding within-host interactions. Compared to
the N752 variant, infections with the D752 variant led to higher levels of viremia and virus-neutralizing
antibody titers [4,5]. This finding is consistent with D752 eliciting a higher immune response and being
more resistant to the response than the N752 variant [16,17].
A growing body of research on this polymorphism has attempted to elucidate the biological
mechanisms connecting DNA polymerase activity to EHM. There is a general consensus that magnitude
and duration of viremia are central aspects of the disease ([18]; reviewed by [19]), with secondary
fevers commonly seen in neurologic cases. Replication kinetics in cultured fibroblasts and epithelial
cells were similar between variants [4]. Studies in primary respiratory epithelial and brain endothelial
model systems have elucidated the ability of D752 strains to modulate immune evasion [20,21]. In nasal
mucosal explants, D752 was more effective at crossing epithelial boundaries [22], but less effective in
vaginal mucosal explants [23]. The ability to infect migratory leukocytes may be a key aspect of EHM
progression, with high levels of nasal virus shedding one of the consequences.
Our finding that neuropathogenicity is linked to nasal virus shedding is consistent with
assumptions underlying the trade-off hypothesis—the currently dominant but still controversial
hypothesis of virulence evolution [24–26]. This hypothesis assumes that virulence evolution is
crucially influenced by a mechanistic link between virulence (defined as increased host death rate)
and pathogen transmission: decreasing virulence constrains pathogen shedding and the related rate at
which pathogens are transmitted to susceptible hosts. This interdependence generates an evolutionary
trade-off for pathogens because the ideal state of low virulence and high transmission rate becomes
impossible to reach. Instead, fitness benefits of reducing virulence come at a fitness cost of a reduced
transmission rate. Although theoretically appealing, there is currently only limited empirical support
for the underlying assumption of virulence–transmission trade-offs [24–34].
In the absence of reliable quantifications of virulence and transmission rates of different EHV-1
strains, it is not possible to directly assess the validity of the trade-off hypothesis for EHV-1.
Nevertheless, our finding of increased and nasal virus shedding for the neuropathogenic EHV-1
variant is fully consistent with this hypothesis. Conceptual descriptions and formal implementations
of the trade-off hypothesis usually assume that pathogens can evolve different levels of virulence
(i.e., increased host death rate) and transmission along a continuous scale [24–26]. In contrast, the
currently existing variation in EHV-1 neuropathogenicity seems to be mainly caused by a single
nucleotide polymorphism, which suggests that a continuous variation in virulence and transmission
might be impossible in this system. As a consequence, it could be possible that there is no single
optimal virulence in this system and that instead both variants permanently coexist [5].
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